Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting.

[1] It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.

[2] In 2018, the US Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron.

[3][4] The combination is also approved for medical use in the European Union,[5] and in Canada.

This drug article relating to the gastrointestinal system is a stub.